Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion-sparing hemostatic agents.

Jason Chiu1, Lloyd H Ketchum, Thomas J Reid

  • 1SUNY-Buffalo, New York, USA.

Current Opinion in Hematology
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2023
Same author

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Gynecologic oncology·2023
Same author

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

Gynecologic oncology·2021
Same author

Fragile-X Syndrome Is Associated With NMDA Receptor Hypofunction and Reduced Dendritic Complexity in Mature Dentate Granule Cells.

Frontiers in molecular neuroscience·2019
Same author

Comparison of precision and speed in laparoscopic and robot-assisted surgical task performance.

The Journal of surgical research·2018
Same author

Efficacy of Implementation of a Chest Pain Center at a Community Hospital.

Critical pathways in cardiology·2017
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

New hemostatic agents can reduce blood loss and minimize transfusions, even without obvious bleeding disorders. This review focuses on pharmaceutical options for various clinical scenarios.

Area of Science:

  • Hematology
  • Pharmacology
  • Surgical Hemostasis

Background:

  • Hemostatic agents are crucial for managing bleeding in diverse clinical situations.
  • Traditional agents are often used for known hemostatic defects.
  • Emerging agents show promise in reducing blood loss irrespective of underlying defects.

Purpose of the Study:

  • To review pharmaceutical agents for improving hemostasis and reducing blood loss.
  • To discuss the application of these agents in various coagulopathic conditions.
  • To highlight strategies for minimizing blood product transfusion.

Main Methods:

  • Literature review of pharmaceutical hemostatic agents.
  • Analysis of agent efficacy in specific clinical settings (e.g., trauma, surgery).

Related Experiment Videos

  • Focus on agents used for clotting factor issues, platelet dysfunction, fibrinolysis, and anticoagulation.

    • Main Results:

    • Multiple pharmaceutical agents are available to enhance hemostasis.
    • These agents can decrease blood loss and transfusion needs across various patient populations.
    • Efficacy is demonstrated in conditions ranging from factor deficiencies to dilution coagulopathy.

    Conclusions:

    • Pharmaceutical interventions offer significant potential for blood loss reduction.
    • Appropriate agent selection can minimize the need for blood product transfusions.
    • Further research into novel hemostatic agents continues to evolve clinical practice.